The derivation and potential use of human embryonic stem cells.
Human embryonic stem cells lines can be derived from human blastocysts at high efficiency (>50%) by immunosurgical isolation of the inner cell mass and culture on embryonic fibroblast cell lines. These cells will spontaneously differentiate into all the primary embryonic lineages in vitro and in vivo, but they are unable to form an integrated embryo or body plan by themselves or when combined with trophectoderm cells. They may be directed into a number of specific cell types and this enrichment process requires specific growth factors, cell-surface molecules, matrix molecules and secreted products of other cell types. Embryonic stem (ES) cells are immortal and represent a major potential for cell therapies for regenerative medicine. Their use in transplantation may depend on the formation of a large bank of suitable human leucocyte antigen (HLA) types or the genetic erasure of their HLA expression. Successful transplantation may also require induction of tolerance in recipients and ongoing immune suppression. Although it is possible to customize ES cells by therapeutic cloning or cytoplasmic transfer, it would appear unlikely that these strategies will be used extensively for producing ES cells compatible for transplantation. Embryonic stem cell research may deliver a new pathway for regenerative medicine.
Trounson
A O
AO
Institute of Reproduction and Development, Monash University, Clayton, Victoria, Australia.
D000818:Animals; D001755:Blastocyst / Q000166:cytology; D002454:Cell Differentiation; D002469:Cell Separation; D002478:Cells, Cultured; D019976:Cloning, Organism; D004622:Embryo, Mammalian / Q000166:cytology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007165:Immunosuppression Therapy; D051379:Mice; D053652:Nuclear Transfer Techniques; D013234:Stem Cells; D013812:Therapeutics